ASH 2023 | Treatment effectiveness of venetoclax-based therapy after BTKi exposure in CLL/SLL
Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, discusses a real-world analysis of data from the Chronic Lymphocytic Leukemia (CLL) Collaborative Study Of Real-World Evidence (CORE) – a retrospective, international, observational study. The results showed that venetoclax, as monotherapy or in combination with rituximab or obinutuzumab, is effective when used in the second or third-line after prior covalent BTK inhibitor (BTKi) exposure in patients with CLL or small lymphocytic lymphoma (SLL). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: AstraZeneca, Janssen, Pharmacyclics, Kite pharma, BMS, Epizyme; Speakers Bureau: TG Therapeutics, Genentech/Roche, Bristol Myers Squibb, Gilead, Morphosys, AbbVie, Pharmacyclics; Honoraria: Seagen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, Beigene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics, Morp; Membership on an entity’s Board of Directors or advisory committees: Roche NHL solutions panel; Consultancy: Seagen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, Beigene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics.
